Alps Advisors Inc. increased its holdings in Theravance Biopharma Inc (NASDAQ:TBPH) by 13.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,951 shares of the biopharmaceutical company’s stock after acquiring an additional 6,938 shares during the period. Alps Advisors Inc.’s holdings in Theravance Biopharma were worth $1,672,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in shares of Theravance Biopharma by 3.6% in the second quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock valued at $144,972,000 after acquiring an additional 126,393 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Theravance Biopharma by 3.8% in the second quarter. Vanguard Group Inc. now owns 3,197,277 shares of the biopharmaceutical company’s stock valued at $127,379,000 after acquiring an additional 116,981 shares in the last quarter. State Street Corp grew its holdings in shares of Theravance Biopharma by 2.2% in the second quarter. State Street Corp now owns 889,682 shares of the biopharmaceutical company’s stock valued at $35,443,000 after acquiring an additional 19,428 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Theravance Biopharma by 6.1% in the second quarter. Northern Trust Corp now owns 530,049 shares of the biopharmaceutical company’s stock valued at $21,117,000 after acquiring an additional 30,611 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Theravance Biopharma by 1.3% during the third quarter. Bank of New York Mellon Corp now owns 210,331 shares of the biopharmaceutical company’s stock valued at $7,202,000 after purchasing an additional 2,624 shares during the period. 86.04% of the stock is owned by institutional investors.
Several equities analysts have weighed in on TBPH shares. BidaskClub raised Theravance Biopharma from a “strong sell” rating to a “sell” rating in a report on Saturday, January 20th. Robert W. Baird reissued a “sell” rating and set a $22.00 price objective on shares of Theravance Biopharma in a report on Wednesday, November 1st. Leerink Swann increased their price objective on Theravance Biopharma from $45.00 to $48.00 and gave the company an “outperform” rating in a report on Thursday. Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, October 25th. Finally, Needham & Company LLC reissued a “buy” rating on shares of Theravance Biopharma in a report on Tuesday, December 5th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Theravance Biopharma currently has a consensus rating of “Hold” and an average target price of $42.00.
Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.05). Theravance Biopharma had a negative net margin of 1,604.87% and a negative return on equity of 99.43%. equities research analysts predict that Theravance Biopharma Inc will post -4.84 EPS for the current year.
TRADEMARK VIOLATION WARNING: This story was posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.com-unik.info/2018/02/10/theravance-biopharma-inc-tbph-stake-boosted-by-alps-advisors-inc.html.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma Inc (NASDAQ:TBPH).
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.